A Cancer-Fighting Version of Herpes Shows Promise in Early Human Trial

A Cancer-Fighting Version of Herpes Shows Promise in Early Human Trial

Scientists may be able to turn a long-time germ foe into a cancer-fighting ally, new research this week suggests. In preliminary data from a Phase I trial, a genetically modified version of the herpes virus has shown promise in treating difficult-to-eradicate tumors, with one patient having experienced a complete remission for 15 months so far. Much more research will be needed to confirm the treatment’s early success, however. The viral treatment is known as RP2 and is a genetically engineered …